PRME vs ALNY vs BEAM vs CRSP vs EDIT

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 127. 0x trailing P/E (44. 2x forward), making it the more compelling value choice. Analysts rate Prime Medicine, Inc. (PRME) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -91. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus EDIT's -90. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.

(ALNY) is the lower-risk stock at 0. 71β versus Editas Medicine, Inc. 's 2. 52β — meaning EDIT is approximately 257% more volatile than ALNY relative to the S&P 500. On balance sheet safety, CRISPR Therapeutics AG (CRSP) carries a lower debt/equity ratio of 21% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alnylam Pharmaceuticals, Inc.

(ALNY) is the more profitable company, earning 8. 4% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRME: 453.

8% to $17. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +411. 9%, EDIT: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRME is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock; BEAM is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.